AstraZeneca (LON:AZN) has announced today that Lokelma has been approved in China for the treatment of adult patients with hyperkalaemia. The approval by the National Medical..

AstraZeneca (LON:AZN) has today announced the US Food and Drug Administration has accepted a supplemental New Drug Application and granted Priority Review for Farxiga to reduce..

AstraZeneca (LON:AZN) and Daiichi Sankyo Company, have today announced that the US Food and Drug Administration has approved Enhertu for the treatment of adult patients with..

AstraZeneca (LON:AZN) today announced that budesonide/glycopyrronium/formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This is the first..

AstraZeneca (LON:AZN) today announced that it has agreed to sell the commercial rights to Arimidex and Casodex in a number of European, African and other countries1..

AstraZeneca (LON:AZN) has completed an agreement to divest its commercial rights to Seroquel and Seroquel XR in Europe and Russia to Cheplapharm Arzneimittel GmbH. Financial considerations..

AstraZeneca (LON:AZN) has today announced that it has received marketing authorisation from China’s National Medical Products Administration for Imfinzi for the treatment of patients with unresectable,..

AstraZeneca (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the companies have..

AstraZeneca (LON:AZN) has agreed to sell the commercial rights to Seroquel and Seroquel XR in the US and Canada to Cheplapharm Arzneimittel GmbH. Seroquel and Seroquel..

AstraZeneca (LON:AZN) today announced that the US Food and Drug Administration has accepted a supplemental Biologics License Application and granted Priority Review for Imfinzi for the..

AstraZeneca (LON:AZN) has announced that the European Commission (EC) has approved Qtrilmet modified-release tablets to improve glycaemic control in adults with type-2 diabetes. The approval is..

AstraZeneca (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) has announced that the US Food..

AstraZeneca (LON:AZN) has presented detailed results from the positive Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of moderate to..

AstraZeneca (LON: AZN) and FibroGen Inc. have presented pooled efficacy and cardiovascular safety analyses from the pivotal Phase III programme assessing roxadustat for the treatment of..

AstraZeneca (LON:AZN) has presented detailed results from the Phase III OLYMPUS and ROCKIES trials showing that roxadustat significantly increased haemoglobin levels in non-dialysis-dependent and dialysis-dependent patients..

AstraZeneca (LON:AZN)has agreed the sale and licence of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe..

AstraZeneca (LON:AZN) announced its year-to-date and Q3 2019 results. Year-to-date Product Sales growth of 13% (17% at CER1) to $17,315m included third-quarter Product Sales of $6,132m..

AstraZeneca (LON:AZN) announced that the US Food and Drug Administration has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults..

AstraZeneca (LON:AZN) and Daiichi Sankyo Company Limited announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for..

Fasenra is now the only respiratory biologic that offers the choice of administration at home or in a doctor’s office with eight-week maintenance dosing AstraZeneca plc..